Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

CD4+ Cells in the Fast Lane - Effect of CAR-T Cells in Focus

15.05.2020

CAR-T cells are T lymphocytes, which exist naturally in the human body. They are genetically modified outside the body to equip them with a new function to kill cancer cells when they are returned to the patient. In current research studies in animal models, researchers of the Paul-Ehrlich-Institut, showed that a sub-group of T immune cells kill cancer cells significantly more effectively than those previously assessed to be the main actors, the CD8+ T cells. Unlike the authorised CAR-T cell medicinal poducts, the research team at the Paul-Ehrlich-Institut generates the CAR T cells directly in the organism. Molecular Therapy reports on the research in its online version of 14.05.2020

Major attention was paid to the marketing authorisation granted by the European Commission in 2018 for two so-called CAR-T cell gene therapy medicinal products.


These are immune cells (T cells) from cancer patients equipped with a synthetic chimeric antigen receptor (CAR) outside the body using genetic engineering methods, propagated, and then returned into the patients’ body.

The antigen receptor exactly matches the specific surface structures on the cancer cells. With the aid of the CAR, the immune cells recognise the cancer cells and kill them.

Thanks to their extraordinary effectiveness, CAR-T cells enjoy major interest: in certain leukaemia patients, where all therapies had previously failed, the cancer was no longer detectable after the CAR-T cell therapy.

The manufacturing of these medicinal products – removal of the cells from the body, genetic modification outside the body, and reinfusion – however, proved to be very complex.

During the same year, scientists of the research team "Molecular Biotechnology and Gene Therapy" headed by Professor Christian Buchholz, succeeded in generating human CAR-T cells in mice in vivo – in other words, directly in the organism.

The transfer of the genetic information for the formation of the CAR proved to be successful with specifically modified lentiviral vector particles (vectors), which transfer the CAR gene exclusively to particular T cell sub-types responsible for combatting the cancer.

When CAR-T cells are manufactured, both so-called CD4 positive (CD4+) and CD8-positive (CD8+) T cells are normally equipped with the chimeric receptor in the mixture. Up to now, it was assumed that, above all, CD8+ CAR T cells eliminate cancer cells.

Now, funded by the German Cancer Aid and the LOEWE centre Frankfurt Cancer Institute, the research group was able to use their method to question a previous postulate. In their tumour mouse model with the human blood system, they used either exclusively CD4-specific or exclusively CD8-specific lentiviral vectors to create CD19-specific CAR T cells in the organism, which were thus targeted to tumour cells and B lymphocytes.

The researchers (m/w/d) tested the activity of the CAR-T cells by measuring the decrease in tumour cells and in B lymphocyte levels. To their surprise, the CD4+ CAR-T cells showed an unexpectedly strong activity which was at least as pronounced as that of the CD8+ CAR-T cells. It can be assumed that this is because the state of exhaustion is reached less rapidly by CD4+ CAR-T cells, especially in the presence of large amounts of tumour cells, than is the case with CD8+ CAR-T cells.

""Our research results point to a more direct role of CD4-positive lymphocytes for the elimination of tumour cells in CAR-T cell therapy"", as Professor Buchholz explained the current results. The latest results will possibly provide another module in generating specific and effective CAR-T cells directly in the patient. However, this will require further pre-clinical and, later on, additional clinical studies.

Originalpublikation:

Agarwal S, Hanauer JDS, Frank AM, Riechert V, Thalheimer FB, Buchholz CJ (2020): In vivo generation of CAR T cells selectively in human CD4+ lymphocytes.
Mol Ther May 14 [Epub ahead of print].

Weitere Informationen:

https://www.pei.de/EN/newsroom/press-releases/year/2020/10-cd4-cells-in-the-fast...

Dr. Susanne Stöcker | idw - Informationsdienst Wissenschaft

More articles from Life Sciences:

nachricht Electrolysis: Chemists at the University of Halle have discovered how to produce better electrodes
14.05.2020 | Martin-Luther-Universität Halle-Wittenberg

nachricht “Off-road” mode enables mobile cells to move freely
14.05.2020 | Institute of Science and Technology Austria

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: 'Hot and messy' entanglement of 15 trillion atoms

Quantum entanglement is a process by which microscopic objects like electrons or atoms lose their individuality to become better coordinated with each other. Entanglement is at the heart of quantum technologies that promise large advances in computing, communications and sensing, for example detecting gravitational waves.

Entangled states are famously fragile: in most cases even a tiny disturbance will undo the entanglement. For this reason, current quantum technologies take...

Im Focus: A new, highly sensitive chemical sensor uses protein nanowires

UMass Amherst team introduces high-performing 'green' electronic sensor

Writing in the journal NanoResearch, a team at the University of Massachusetts Amherst reports this week that they have developed bioelectronic ammonia gas...

Im Focus: Surgery Training with Robots and Virtual Reality

Joint press release from the University of Bremen and Chemnitz University of Technology

The insertion of hip implants places high demands on surgeons. To help young doctors practice this operation under realistic conditions, scientists from the...

Im Focus: Technology innovation for neurology: Brain signal measurement using printed tattoo electrodes

TU Graz researcher Francesco Greco has developed ultra-light tattoo electrodes that are hardly noticeable on the skin and make long-term measurements of brain activity cheaper and easier.

In 2015 Francesco Greco, head of the Laboratory of Applied Materials for Printed and Soft electronics (LAMPSe, http://lampselab.com/) at the Institute of Solid...

Im Focus: Future information technologies: 3D Quantum Spin Liquid revealed

Quantum Spin Liquids are candidates for potential use in future information technologies. So far, Quantum Spin Liquids have usually only been found in one or two dimensional magnetic systems only. Now an international team led by HZB scientists has investigated crystals of PbCuTe2O6 with neutron experiments at ISIS, NIST and ILL. They found spin liquid behaviour in 3D, due to a so called hyper hyperkagome lattice. The experimental data fit extremely well to theoretical simulations also done at HZB.

IT devices today are based on electronic processes in semiconductors. The next real breakthrough could be to exploit other quantum phenomena, for example...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Aachen Machine Tool Colloquium AWK'21 will take place on June 10 and 11, 2021

07.04.2020 | Event News

International Coral Reef Symposium in Bremen Postponed by a Year

06.04.2020 | Event News

13th AKL – International Laser Technology Congress: May 4–6, 2022 in Aachen – Laser Technology Live already this year!

02.04.2020 | Event News

 
Latest News

CD4+ Cells in the Fast Lane - Effect of CAR-T Cells in Focus

15.05.2020 | Life Sciences

'Hot and messy' entanglement of 15 trillion atoms

15.05.2020 | Physics and Astronomy

A soft touch for robotic hardware

15.05.2020 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>